肝细胞癌一线全身治疗的优先要求：疗效广泛且毒性较小 - Suppr

Suppr

超能文献

Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

出版信息

Liver Cancer. 2023 Jan 6;12(1):1-6. doi: 10.1159/000528979. eCollection 2023 Feb.

DOI:10.1159/000528979

PMID:36909143

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9999599/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b98/9999599/8fa9aaf4951a/lic-0012-0001-gu01.jpg

相似文献

Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity.肝细胞癌一线全身治疗的优先要求：疗效广泛且毒性较小

Liver Cancer. 2023 Jan 6;12(1):1-6. doi: 10.1159/000528979. eCollection 2023 Feb.

Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting.阿替利珠单抗联合贝伐单抗与曲美木单抗联合度伐单抗在真实世界中治疗肝细胞癌（HCC）患者的疗效比较

Target Oncol. 2025 Jun 23. doi: 10.1007/s11523-025-01161-5.

Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal.两例晚期肝细胞癌患者在阿替利珠单抗联合贝伐单抗治疗期间疾病进展且停用贝伐单抗后，接受度伐利尤单抗联合曲美木单抗治疗取得良好疗效。

Cureus. 2023 Sep 16;15(9):e45385. doi: 10.7759/cureus.45385. eCollection 2023 Sep.

Cost-effectiveness of first-line systemic therapies for unresectable hepatocellular carcinoma.不可切除肝细胞癌一线全身治疗的成本效益

Br J Clin Pharmacol. 2024 Dec 18. doi: 10.1111/bcp.16367.

Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.度伐利尤单抗/替西木单抗在阿替利珠单抗/贝伐珠单抗治疗后作为免疫检查点抑制剂再次挑战用于不可切除肝细胞癌的疗效和安全性。

Target Oncol. 2024 Sep;19(5):769-778. doi: 10.1007/s11523-024-01092-7. Epub 2024 Sep 2.

Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma.评估免疫检查点抑制剂的两种再激发策略：度伐利尤单抗联合曲美木单抗用于晚期肝细胞癌

Hepatol Res. 2025 May;55(5):718-729. doi: 10.1111/hepr.14160. Epub 2025 Jan 15.

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.系统治疗晚期肝细胞癌指南推荐的批判性评价：综述。

JAMA Oncol. 2024 Mar 1;10(3):395-404. doi: 10.1001/jamaoncol.2023.2677.

Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.晚期肝细胞癌一线全身治疗的疗效与耐受性平衡：一项网状Meta分析

Liver Cancer. 2023 Jul 25;13(2):169-180. doi: 10.1159/000531744. eCollection 2024 Apr.

Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma.度伐利尤单抗联合曲美木单抗作为不可切除肝细胞癌患者一线治疗的成本效益分析

Ther Adv Med Oncol. 2024 Sep 18;16:17588359241274625. doi: 10.1177/17588359241274625. eCollection 2024.

Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment-Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab.既往免疫检查点抑制剂治疗是使用度伐利尤单抗联合曲美木单抗治疗不可切除肝细胞癌时发生治疗相关不良事件的一个危险因素。

JGH Open. 2025 Apr 23;9(4):e70163. doi: 10.1002/jgh3.70163. eCollection 2025 Apr.

引用本文的文献

Usefulness of the Early Increase of Peripheral Blood Lymphocyte Count in Predicting Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab.外周血淋巴细胞计数早期升高对预测接受度伐利尤单抗联合曲美木单抗治疗的晚期肝细胞癌患者临床结局的价值

Cancers (Basel). 2025 Apr 9;17(8):1274. doi: 10.3390/cancers17081274.

Treatment Decision-Making in Unresectable Hepatocellular Carcinoma: Importance of Understanding the Different Response Patterns between IO plus Anti-VEGF and IO plus IO Regimens.不可切除肝细胞癌的治疗决策：理解免疫治疗联合抗血管生成药物与免疫治疗联合免疫治疗方案不同反应模式的重要性

Liver Cancer. 2025 Mar 7;14(2):119-126. doi: 10.1159/000545163. eCollection 2025 Apr.

Prediction of Pathologic Response in Unresectable Hepatocellular Carcinoma After Downstaging with Locoregional and Systemic Combination Therapy.经局部区域和全身联合治疗降期后不可切除肝细胞癌病理反应的预测

J Hepatocell Carcinoma. 2025 Jan 16;12:43-58. doi: 10.2147/JHC.S499597. eCollection 2025.

Global perspectives and hotspots of VEGF signaling pathway in liver disease from 2008 to 2023: A bibliometric analysis and visualization.2008年至2023年肝脏疾病中VEGF信号通路的全球视角与热点：文献计量分析与可视化

Heliyon. 2024 Dec 19;11(1):e41346. doi: 10.1016/j.heliyon.2024.e41346. eCollection 2025 Jan 15.

Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.日本肝细胞癌的当前治疗策略

Liver Cancer. 2023 Oct 3;12(6):497-509. doi: 10.1159/000534304. eCollection 2023 Dec.

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.接受联合免疫治疗联合局部区域治疗后达到临床完全缓解的肝细胞癌患者的停药标准

Liver Cancer. 2023 Jul 28;12(4):289-296. doi: 10.1159/000532023. eCollection 2023 Sep.

Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma.免疫检查点抑制剂与局部区域治疗联合用于肝细胞癌的治疗

Cancers (Basel). 2023 Oct 20;15(20):5072. doi: 10.3390/cancers15205072.

Serum resistin and the risk for hepatocellular carcinoma in diabetic patients.血清抵抗素与糖尿病患者肝细胞癌的风险。

World J Gastroenterol. 2023 Jul 21;29(27):4271-4288. doi: 10.3748/wjg.v29.i27.4271.

本文引用的文献

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。

NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.

Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的白蛋白-胆红素分级分析：III期IMbrave150研究的事后分析

Liver Cancer. 2023 Mar 4;12(5):479-493. doi: 10.1159/000529996. eCollection 2023 Oct.

Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗晚期肝细胞癌患者的生存替代终点。

Immunotherapy. 2022 Nov;14(16):1341-1351. doi: 10.2217/imt-2022-0089. Epub 2022 Oct 26.

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗序贯根治性转化（ABC转化）用于不可切除、不适合经动脉化疗栓塞术的中期肝细胞癌患者

Liver Cancer. 2022 Jul 27;11(5):399-406. doi: 10.1159/000526163. eCollection 2022 Sep.

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.卡博替尼联合阿替利珠单抗与索拉非尼治疗晚期肝细胞癌（COSMIC-312）：一项多中心、开放标签、随机、III 期临床试验。

Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.

A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.一种针对不适合经动脉化疗栓塞术（TACE）的中期肝癌患者的新型治疗策略：先行全身治疗，随后进行根治性转化治疗。

Liver Cancer. 2021 Oct 12;10(6):539-544. doi: 10.1159/000519749. eCollection 2021 Nov.

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。

Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。

J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.

Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌韩国患者的疗效和安全性。

Liver Int. 2022 Mar;42(3):674-681. doi: 10.1111/liv.15102. Epub 2021 Nov 29.

Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.贝伐珠单抗联合阿替利珠单抗治疗不可切除肝细胞癌的真实世界实践：日本患者的早期经验。

Invest New Drugs. 2022 Apr;40(2):392-402. doi: 10.1007/s10637-021-01185-4. Epub 2021 Sep 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验